About Arrakis Therapeutics
Arrakis Therapeutics is a company based in Waltham (United States) founded in 2015 by Raj Parekh.. Arrakis Therapeutics has raised $113 million across 2 funding rounds from investors including Pfizer, ARE and WuXi AppTec. The company has 91 employees as of December 31, 2023. Arrakis Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Horizon Discovery, Revolution Medicines, Blueprint Medicines and Syndax, among others.
- Headquarter Waltham, United States
- Employees 91 as on 31 Dec, 2023
- Founders Raj Parekh
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arrakis Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$113 M (USD)
in 2 rounds
-
Latest Funding Round
$75 M (USD), Series B
Apr 18, 2019
-
Investors
Pfizer
& 12 more
-
Employee Count
91
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Arrakis Therapeutics
Arrakis Therapeutics has successfully raised a total of $113M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $75.0M
-
First Round
First Round
(27 Feb 2017)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2019 | Amount | Series B - Arrakis Therapeutics | Valuation | VenBio , Nextech Invest | |
| Feb, 2017 | Amount | Series A - Arrakis Therapeutics | Valuation | Canaan |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arrakis Therapeutics
Arrakis Therapeutics has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Pfizer, ARE and WuXi AppTec. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arrakis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Arrakis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arrakis Therapeutics Comparisons
Competitors of Arrakis Therapeutics
Arrakis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Horizon Discovery, Revolution Medicines, Blueprint Medicines and Syndax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Genetically modified cell lines are developed using AAV gene-editing platform.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arrakis Therapeutics
Frequently Asked Questions about Arrakis Therapeutics
When was Arrakis Therapeutics founded?
Arrakis Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Arrakis Therapeutics located?
Arrakis Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Arrakis Therapeutics a funded company?
Arrakis Therapeutics is a funded company, having raised a total of $113M across 2 funding rounds to date. The company's 1st funding round was a Series A of $38M, raised on Feb 27, 2017.
How many employees does Arrakis Therapeutics have?
As of Dec 31, 2023, the latest employee count at Arrakis Therapeutics is 91.
What does Arrakis Therapeutics do?
Arrakis Therapeutics was founded in 2015 in Waltham, United States, within the biotechnology sector. Tools for RNA structure analysis are offered through bioinformatics platforms. These enable identification of RNA targets, design of drug molecules, and selection of therapeutic candidates. Novel drugs are under development for conditions including cancer, central nervous system diseases, and rare genetic disorders, with operations focused on advancing RNA-targeted therapies.
Who are the top competitors of Arrakis Therapeutics?
Arrakis Therapeutics's top competitors include Jazz Pharmaceuticals, Horizon Discovery and C4 Therapeutics.
Who are Arrakis Therapeutics's investors?
Arrakis Therapeutics has 13 investors. Key investors include Pfizer, ARE, WuXi AppTec, Celgene, and Canaan.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.